Dulaglutide vs Alpha-Defensin
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Dulaglutide
Dulaglutide (Trulicity) is a once-weekly GLP-1 receptor agonist for type 2 diabetes. Its larger molecular size from fusion with an Fc fragment extends half-life and may reduce some GI side effects.
Full details →Alpha-Defensin
Alpha-defensins are small cationic peptides that are key components of the innate immune system. They have broad-spectrum antimicrobial activity against bacteria, fungi, and some viruses.
Full details →Side-by-Side Comparison
| Aspect | Dulaglutide | Alpha-Defensin |
|---|---|---|
| Mechanism | GLP-1 analog fused to a modified human IgG4 Fc fragment, providing extended duration of action. Activates GLP-1 receptors for glucose-dependent insulin secretion and appetite suppression. | Insert into microbial membranes to form pores, leading to cell death. Also have immunomodulatory effects including chemotaxis of immune cells and cytokine modulation. |
| Typical Dosage | Start at 0.75mg once weekly, may increase to 1.5mg, 3mg, or maximum 4.5mg weekly based on glycemic response. | Research compound - dosing varies by application. Typically studied in laboratory and early clinical research settings rather than for general use. |
| Administration | Subcutaneous injection once weekly, any time of day, with or without food. Comes in pre-filled single-dose pens. | Various routes studied including topical, local injection, and systemic administration depending on application. |
| Side Effects | Nausea, diarrhea, vomiting, abdominal pain, decreased appetite. Generally well-tolerated with gradual dose titration. | Limited human use data. May cause local inflammation. Potential for immune activation effects. |
| Best For |